Genomic Variation and Treatment Strategies of COVID-19: A Descriptive Review

Coronavirus disease 2019 (COVID-19) was spread across China and affected more than 180 countries worldwide to date. SARS-CoV-2 is a beta coronavirus that shows genomic similarity with bat coronaviruses. The intermediate source in human viral transmission caused by dromedary camels for MERS-CoV civet cats SARS-CoV. Transmission of the virus from human-to-human achieved through close contact infected persons. genome consists four structural proteins, including Spike (S), Membrane (M), Envelop (E), Nucleocapsid (N) proteins. These proteins are encoded within 3' end. spike protein responsible attachment host cell surface receptors (angiotensin converting enzyme-2 receptor), resulting fusion subsequently damage. N protein, after binding, causes RNA changes. accessory present SARS-CoV open read frames (ORFs) very similar COVID 19. COVID-19 infection triggered number deaths even now affecting confirmed cases. patients characterized pneumonia, cytokine storms, weakened lymphocytes, lymphocytopenia, respiratory failure. However, lack antiviral vaccines permits emergency clinical trials since January 2020. Recently, several anti-viral drugs being repositioned restructured as part an immediate investigation. In this review, we discussed sequence SARS-CoV-2, its different features current therapeutic strategies combat serious condition.